A5063412971- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Retinoids in leukemia and cellular processes
- Chronic Myeloid Leukemia Treatments
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Hematopoietic Stem Cell Transplantation
- Advanced biosensing and bioanalysis techniques
- Hemoglobinopathies and Related Disorders
- Cancer, Hypoxia, and Metabolism
- Hematological disorders and diagnostics
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- PARP inhibition in cancer therapy
- Immune cells in cancer
- Peptidase Inhibition and Analysis
- RNA Interference and Gene Delivery
- Renal and related cancers
- MicroRNA in disease regulation
- Ubiquitin and proteasome pathways
- Cell death mechanisms and regulation
- Epigenetics and DNA Methylation
- Eosinophilic Disorders and Syndromes
- Drug-Induced Ocular Toxicity
University of Rome Tor Vergata
2013-2022
University of Pisa
2019
Fondazione Santa Lucia
2010-2015
Policlinico Tor Vergata
2010
St. Eugenio Hospital
2010
We evaluated leukemia-associated immunophenotypes (LAIP) and their correlation with fms-like tyrosine kinase 3 (FLT3) nucleophosmin (NPM1) gene mutational status in order to contribute a better identification of patients at highest risk relapse acute myeloid leukemia (AML).Bone marrow samples from 132 AML were analyzed by nine-color multiparametric flow cytometry. confirmed the presence mutation diagnostic sorted cells conventional RT-PCR patient-specific RQ-PCR.Within CD34(+) cell fraction,...
Abstract The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML), compared placebo. In this post hoc subgroup analysis trial, we evaluated impact of 163 FLT3-tyrosine domain (TKD) mutations. At a median follow-up 60.7 months (95% CI, 55.0-70.8), 5-year event-free survival (EFS) rate was higher...
The E3 ubiquitin ligase (E3) WWP1 is an oncogenic factor implicated in the maintenance of different types epithelial cancers. role WW domain-containing protein 1 (WWP1) haematological neoplasms remains unknown. Acute myeloid leukaemia (AML) characterized by expansion malignant cells blocked at stages differentiation. Here we report that expression significantly augmented a large cohort primary AML patients and cell lines, compared with haematopoietic from healthy donors. We show inactivation...
Summary FLT3 internal tandem duplication (ITD) mutations are frequently detected at diagnosis in cytogenetically normal acute myeloid leukaemia (CN‐AML) and predict unfavourable outcome. ITD is an unstable aberration may be lost or acquired relapse. Recent whole genome sequencing studies have suggested that + ve AML relapse evolve from small subclones undetectable by routine polymerase chain reaction (PCR). We developed a patient‐specific real‐time quantitative‐PCR (RQ‐PCR) to implement...
Abstract Despite the high probability of cure patients with acute promyelocytic leukemia (APL), mechanisms relapse are still largely unclear. Mutational profiling at diagnosis and/or may help to identify APL needing frequent molecular monitoring and early treatment intervention. Using an NGS approach including a 31 myeloid gene‐panel, we tested BM samples 44 APLs time diagnosis, relapse. Mutations in PML RARA genes were studied using customized‐NGS‐RNA panel. Patients relapsing after...
Key Points RA synergizes with the N-glycosylation inhibitor tunicamycin and ATO to induce AML cell death via generation of ER oxidative stress.
Once the diagnostic suspicion of acute promyelocytic leukemia (APL) has been raised, international guidelines recommend prompt initiation tailored therapy and supportive care, while awaiting for genetic confirmation diagnosis, identification specific PML/RARA isoform by reverse transcriptase polymerase chain reaction (RT-PCR). Depending on PML break point, usually located within intron 6, exon or 3, different transcript isoforms may be generated, that is, long (bcr1), variant (bcr2), short...
Using a multiparametric flow cytometry assay, we assessed the predictive power of threshold calculated applying criteria limit detection (LOD) and quantitation (LOQ) in adult patients with acute myeloid leukemia. This was post-hoc analysis 261 enrolled GIMEMA AML1310 prospective trial. According to protocol design, using predefined measurable residual disease (MRD) 0.035% bone marrow leukemic cells (RLC) on mononuclear cells, 154 (59%) were negative (MRD <0.035%) 107 (41%) positive...
Abstract The translocation t(16;21) involving RUNX1 ( AML1 ) and resulting in the RUNX1‐CBFA2T3 fusion is a rare but recurrent abnormality mostly found therapy‐related acute myeloid leukemia (t‐AML) associated with agents targeting topoisomerase II (topo II). We characterized, at genomic level, patient who developed t‐AML after treatment of multiple sclerosis mitoxantrone (MTZ). Long template nested PCR DNA followed by direct sequencing enabled localization CBFA2T3 ETO2 breakpoints introns 5...